Treatment-Resistant Depression: Recovery Is Possible

What WebMD's Coverage Signals About TRD in 2026

A new piece from WebMD, published June 29, 2026, addresses recovery from treatment-resistant depression — a topic that has grown significantly more relevant as newer rapid-acting treatments have entered mainstream awareness. For readers researching low-dose ketamine, this kind of mainstream health coverage matters: it shapes what patients ask their clinicians, what clinicians feel pressure to offer, and how recovery itself gets defined.

Treatment-resistant depression (TRD) is generally defined as major depressive disorder that has not adequately responded to at least two separate antidepressant trials of sufficient dose and duration. Estimates suggest that roughly 30% of people with major depression fall into this category at some point, making TRD one of the most clinically consequential and under-discussed problems in psychiatry.

When a trusted consumer health platform like WebMD covers TRD recovery, it reflects growing public recognition that conventional antidepressants do not work for everyone — and that alternatives deserve serious attention. For the low-dose ketamine community, that recognition is overdue.

Why TRD Recovery Looks Different Than Standard Depression Recovery

Recovery from TRD is not simply a matter of waiting longer or switching antidepressants again. Research published over the past decade has made clear that after multiple failed medication trials, the probability of remission from the next conventional antidepressant drops substantially. The STAR*D trial, one of the largest depression treatment studies ever conducted, found that cumulative remission rates declined with each successive treatment step — meaning patients who have already tried and failed multiple medications face increasingly steep odds with each additional standard-of-care attempt.

This is the clinical reality that makes ketamine — including sub-anesthetic, low-dose ketamine infusions administered in outpatient settings — a meaningful development in TRD treatment. Unlike traditional antidepressants, which work primarily through serotonin, dopamine, or norepinephrine pathways and typically require weeks to show effect, ketamine acts on the glutamate system and can produce measurable antidepressant effects within hours to days for many patients.

For people who have spent years trying medications, adjusting doses, switching drugs, and managing side effects with little lasting relief, that speed of response is not a minor convenience. For some patients, it is the first signal in years that relief is biologically possible for them.

What Recovery Actually Requires: Sustaining Initial Response

One of the most important distinctions in the ketamine literature — and one that mainstream coverage sometimes glosses over — is the difference between response and sustained recovery. Ketamine, in many studies, produces rapid response rates that outpace those of traditional antidepressants in TRD populations. However, the antidepressant effects of a single infusion or a short series of infusions are typically not permanent. For most patients, maintenance dosing — whether through periodic infusions, oral ketamine formulations, or nasal esketamine (Spravato) — plays an important role in sustaining improvement.

This is not a criticism of ketamine; it mirrors the reality of antidepressant maintenance therapy broadly. Most people who achieve remission from major depression with standard antidepressants are advised to continue medication for at least six to twelve months, and often longer. TRD complicates this picture further because the underlying biology is more treatment-resistant, and the threshold for relapse may be lower.

Clinically, this means that for patients exploring low-dose ketamine as part of their TRD recovery, the conversation with their provider should extend beyond the initial induction series. Questions worth asking include: How will we know if the response is holding? What is the plan if symptoms begin to return between sessions? Are there adjunctive therapies — psychotherapy, lifestyle interventions, or other medications — that can help consolidate the gains made during ketamine treatment?

What Growing Mainstream Coverage Means for Patients and Clinicians

The broader significance of platforms like WebMD covering TRD recovery is that it normalizes patient-initiated conversations about treatment options that were once considered last resort. That normalization is largely positive: it reduces stigma, encourages people who have been suffering silently to seek more aggressive evaluation, and can prompt primary care physicians to refer patients to psychiatrists or ketamine specialists earlier rather than after years of failed trials.

There are also limits to what any single health article can convey about TRD recovery. Individual response to ketamine varies. Not every patient who tries low-dose ketamine achieves remission. Screening for dissociative risk, cardiovascular status, substance use history, and other contraindications is essential before starting treatment. The evidence base continues to evolve, and optimal dosing protocols, spacing of maintenance sessions, and long-term outcomes are still areas of active research.

For readers of this site who are already in treatment or considering it, the most useful frame is this: mainstream coverage of TRD recovery reflects a real shift in what psychiatry now considers achievable. Ketamine is a significant part of that shift. The work of turning that potential into durable personal recovery still requires individualized clinical care, realistic expectations, and ongoing monitoring — not just a short course of infusions and a hopeful headline.

If you are researching low-dose ketamine for treatment-resistant depression, the clinical conversation is worth having now. The evidence base, the available formulations, and the clinical infrastructure supporting ketamine treatment have all expanded substantially. Recovery from TRD is not guaranteed, but it is no longer the long shot it once was.